Official Conference Coverage of the 2014 Annual Meeting of the American Association for the Study of Liver Diseases
Capsule Summaries
Reviews by expert faculty on key studies highlighted at the conference
Downloadable slides
Review Conference Coverage
Ledipasvir/Sofosbuvir Regimens Highly Effective, Safe, and Well Tolerated in Patients With Genotype 1 HCV and Compensated Cirrhosis
Similar SVR12 rates with 24-week ribavirin-free regimen vs 12-week ribavirin-containing regimen in treatment-experienced cirrhotics.
Review the Full Capsule
HCV-TARGET: Real-World Use of Sofosbuvir-Containing Regimens Yields Overall SVR4 Rates ≥ 85% in Patients With Genotype 1 or 2 HCV Infection
To date, regimens allowing removal of peginterferon most commonly selected: sofosbuvir plus ribavirin in patients with genotype 2/3 infection and sofosbuvir plus simeprevir with or without ribavirin in genotype 1 HCV infection.
Review the Full Capsule
ELECTRON-2: High SVR12 Rates With Sofosbuvir + NS5A Inhibitor GS-5816 With or Without Ribavirin in Treatment-Naive, Noncirrhotic Genotype 3 HCV-Infected Patients in Phase II Trial
Low levels of discontinuation due to adverse events; no virologic failure with 100-mg dose of GS-5816. Inclusion of ribavirin associated with more frequent adverse events with no efficacy benefit.
Review the Full Capsule
ALLY-3: High SVR12 Rates With 12 Weeks of Daclatasvir + Sofosbuvir in Treatment-Naive or Treatment-Experienced Patients With Genotype 3 HCV Infection
SVR12 rates substantially lower for both treatment-naive and treatment-experienced cirrhotics vs noncirrhotics.
Review the Full Capsule
Final C-WORTHY Results: Grazoprevir + Elbasvir ± RBV Yields High SVR12 Rates in Genotype 1 Treatment-Naive Cirrhotic Patients and Previous Null Responders
SVR12 rates ≥ 90% were attained regardless of RBV use or treatment duration.
Review the Full Capsule
No comments:
Post a Comment